FDA supplemental approval: Fortamet (Labeling)

AI Summary

This is a regulatory approval document for a labeling supplement to Fortamet (metformin HCl extended-release), approved on 11 August 2026. The FDA determined the product was not discontinued or withdrawn for safety or effectiveness reasons. No clinical trial results, efficacy data, or comparative evidence are contained in this regulatory record.

Plain-language summary

FDA supplemental approval for labeling changes to an established metformin extended-release product; does not contain clinical trial data or efficacy evidence.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This labeling approval does not provide evidence of clinical benefit, efficacy, or safety outcomes. Clinicians should consult the approved labeling and prescribing information for indications, dosing, and warnings; this record alone does not support clinical decision-making.

Caveats

• This record does not contain clinical trial results, efficacy data, or safety trial outcomes.
• The specific labeling changes approved are not detailed in this regulatory notice.
• No comparative efficacy or safety data are reported.
• The determination of non-discontinuation does not constitute evidence of product performance or benefit.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.